X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9063) 9063
Book Review (3387) 3387
Publication (639) 639
Book Chapter (82) 82
Newsletter (46) 46
Conference Proceeding (24) 24
Book / eBook (18) 18
Magazine Article (9) 9
Reference (7) 7
Dissertation (6) 6
Newspaper Article (3) 3
Transcript (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7847) 7847
humans (6815) 6815
male (3672) 3672
hypertension (3167) 3167
female (3083) 3083
angiotensin (2325) 2325
middle aged (2324) 2324
hypertension - drug therapy (2300) 2300
angiotensin-converting enzyme inhibitors - therapeutic use (2200) 2200
animals (2192) 2192
aged (2074) 2074
angiotensin ii type 1 receptor blockers - therapeutic use (1652) 1652
antihypertensive agents - therapeutic use (1633) 1633
pharmacology & pharmacy (1600) 1600
cardiac & cardiovascular systems (1568) 1568
treatment outcome (1565) 1565
risk factors (1402) 1402
blood pressure - drug effects (1396) 1396
heart failure (1301) 1301
adult (1269) 1269
renin-angiotensin system (1260) 1260
blood-pressure (1244) 1244
peripheral vascular disease (1235) 1235
drug therapy (1197) 1197
drug therapy, combination (1163) 1163
mortality (1156) 1156
medicine & public health (1153) 1153
renin-angiotensin system - drug effects (1148) 1148
blood pressure (1065) 1065
hypertension - physiopathology (1011) 1011
abridged index medicus (956) 956
angiotensin ii type 1 receptor blockers - adverse effects (932) 932
tetrazoles - therapeutic use (884) 884
rats (878) 878
cardiology (864) 864
angiotensin-ii (863) 863
diabetes (852) 852
research (830) 830
angiotensin-converting enzyme inhibitors - adverse effects (816) 816
heart failure - drug therapy (807) 807
care and treatment (796) 796
urology & nephrology (791) 791
health aspects (776) 776
ace inhibitors (758) 758
antihypertensive agents - adverse effects (756) 756
internal medicine (755) 755
enzymes (748) 748
analysis (731) 731
valsartan (672) 672
angiotensin ii (671) 671
medicine, general & internal (663) 663
losartan (655) 655
oxidative stress (652) 652
heart-failure (634) 634
double-blind method (627) 627
hypertension - complications (625) 625
aged, 80 and over (613) 613
angiotensin ii type 1 receptor blockers - pharmacology (609) 609
cardiovascular disease (594) 594
myocardial-infarction (587) 587
double-blind (580) 580
prevention (575) 575
adrenergic beta-antagonists - therapeutic use (568) 568
time factors (565) 565
prospective studies (550) 550
cardiovascular (539) 539
risk (539) 539
benzimidazoles - therapeutic use (536) 536
renin-angiotensin system - physiology (536) 536
aldosterone (527) 527
angiotensin-converting enzyme inhibitors - pharmacology (521) 521
tetrazoles - adverse effects (517) 517
angiotensin receptor antagonists (512) 512
therapy (512) 512
angiotensin ii type 1 receptor blockers - administration & dosage (509) 509
calcium channel blockers - therapeutic use (502) 502
angiotensin receptor antagonists - therapeutic use (487) 487
antihypertensive agents - administration & dosage (481) 481
kidney diseases (476) 476
randomized controlled trials as topic (472) 472
diuretics (471) 471
physiological aspects (471) 471
antihypertensive agents - pharmacology (468) 468
heart failure - physiopathology (463) 463
cardiovascular diseases (458) 458
rodents (458) 458
enzyme inhibitors (454) 454
dose-response relationship, drug (453) 453
clinical trials (452) 452
dosage and administration (452) 452
endocrinology & metabolism (440) 440
heart (435) 435
left-ventricular dysfunction (435) 435
angiotensin-converting enzyme inhibitors - administration & dosage (434) 434
diuretics - therapeutic use (426) 426
nephrology (424) 424
angiotensin-converting enzyme inhibitors (421) 421
follow-up studies (416) 416
mice (414) 414
inflammation (412) 412
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9009) 9009
German (69) 69
Spanish (30) 30
Japanese (28) 28
French (19) 19
Russian (12) 12
Chinese (7) 7
Danish (4) 4
Norwegian (4) 4
Swedish (4) 4
Czech (3) 3
Italian (3) 3
Korean (3) 3
Portuguese (3) 3
Hungarian (2) 2
Polish (2) 2
Romanian (2) 2
Dutch (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 741 - 750
Summary Background Raised blood pressure is common in acute stroke, and is associated with an increased risk of poor outcomes. We aimed to examine whether... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DESIGN | MANAGEMENT | ACUTE ISCHEMIC STROKE | INTRAVENOUS NIMODIPINE | GUIDELINES | CEREBRAL-HEMORRHAGE TRIAL | OUTCOMES | BLOOD-PRESSURE REDUCTION | HYPERTENSION | INTERVENTION | Meta-Analysis as Topic | Angiotensin II Type 1 Receptor Blockers - adverse effects | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Stroke - physiopathology | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Treatment Failure | Aged, 80 and over | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Odds Ratio | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Brain Ischemia - complications | Double-Blind Method | Drug Administration Schedule | Europe | Stroke - drug therapy | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Regression Analysis | Stroke - etiology | Aged | Tetrazoles - adverse effects | Cerebral Hemorrhage - complications | Hypertension | Stroke (Disease) | Complications and side effects | Candesartan | Research | Drug therapy | Health aspects | Studies | Stroke | Blood pressure | Clinical medicine | Index Medicus | Abridged Index Medicus | blood pressure | Hospitals | stroke | Mortality | myocardial infarction | composite materials | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2009, Volume 361, Issue 1, pp. 40 - 51
This study aimed to determine whether early administration of drugs that block the renin–angiotensin system slows the progression of change in glomerular... 
CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | STRUCTURAL-FUNCTIONAL RELATIONSHIPS | CORTICAL INTERSTITIUM | BLOOD-PRESSURE CONTROL | EARLY NATURAL-HISTORY | RETINOPATHY | ANGIOTENSIN-CONVERTING ENZYME | NEPHROPATHY | PROGRESSION | ENDOTHELIAL GROWTH-FACTOR | Retina - drug effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Male | Albuminuria | Angiotensin II Type 1 Receptor Blockers - pharmacology | Enalapril - therapeutic use | Enalapril - adverse effects | Mesangial Cells - drug effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Diabetic Nephropathies - prevention & control | Double-Blind Method | Diabetes Mellitus, Type 1 - physiopathology | Kidney Glomerulus - drug effects | Diabetes Mellitus, Type 1 - pathology | Kaplan-Meier Estimate | Losartan - pharmacology | Logistic Models | Kidney Glomerulus - pathology | Disease Progression | Diabetes Mellitus, Type 1 - drug therapy | Diabetic Retinopathy - prevention & control | Enalapril - pharmacology | Losartan - therapeutic use | Mesangial Cells - pathology | Losartan - adverse effects | Renin-Angiotensin System - drug effects | Retina - pathology | Diabetic retinopathy | Control | Usage | Enalapril | Type 1 diabetes | Patient outcomes | Losartan | Enalaprilat | Drug therapy | Kidneys | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9638, pp. 547 - 553
Summary Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination... 
Internal Medicine | COOPERATE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | RENIN-ANGIOTENSIN SYSTEM | DISEASE | PROTEINURIA | CONVERTING ENZYME-INHIBITORS | COMBINATION | NEPHROPATHY | II RECEPTOR BLOCKERS | PROGRESSION | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Ramipril - administration & dosage | Proteinuria - chemically induced | Cardiovascular Diseases - complications | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Benzimidazoles - therapeutic use | Kidney - drug effects | Double-Blind Method | Diabetes Mellitus - drug therapy | Proteinuria - metabolism | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Benzoates - administration & dosage | Creatinine - blood | Aged | Urine | Drugs | Studies | Kidneys | Disease | Clinical trials | Risk | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 16, pp. 1685 - 1697
Persons with prehypertension (formerly, “borderline hypertension”) were randomly assigned in a blinded fashion to receive two years of candesartan or placebo,... 
UNITED-STATES | SPONTANEOUSLY HYPERTENSIVE RATS | MEDICINE, GENERAL & INTERNAL | NORMAL BLOOD-PRESSURE | METABOLIC CHARACTERISTICS | RISK-FACTORS | CONVERTING-ENZYME-INHIBITOR | CLINICAL-TRIAL | BORDERLINE HYPERTENSION | PREVENTION | PROGRESSION | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tetrazoles - pharmacology | Dyslipidemias - complications | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Feasibility Studies | Incidence | Biphenyl Compounds - pharmacology | Hypertension - prevention & control | Adult | Female | Blood Pressure - drug effects | Hypertension - epidemiology | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Obesity - complications | Logistic Models | Obesity - physiopathology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Benzimidazoles - pharmacology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Dyslipidemias - physiopathology | Hypertension | Dosage and administration | Research | Drug therapy | Candesartan | Automation | Blood pressure | Lifestyles | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting–enzyme inhibitor ramipril, and combination therapy with both... 
MEDICINE, GENERAL & INTERNAL | DESIGN | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | DOUBLE-BLIND | SYSTOLIC DYSFUNCTION | RANDOMIZED CLINICAL-TRIALS | CONGESTIVE-HEART-FAILURE | COMBINATION | CONVERTING-ENZYME-INHIBITORS | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 20, pp. 1892 - 1903
Journal Article